NBIX NEUROCRINE BIOSCIENCES INC
Price Chart
Executive Summary
Three C-suite officers at Neurocrine Biosciences sold a total of ~$2.73M in open-market shares within a 7-day window. All sales followed derivative exercises (non-cash M and A), and one officer (Boyer D.) sold without a prior M, which is routine compensation-driven selling. At $16.6B market cap, the cluster is ~0.016% of cap — below the 0.1% materiality floor for insider sales, rendering the cluster classificationally trivial. Per the asymmetry rule for sales (Alldredge 2019), no amplification is applied.
Key Financial Metrics
Actionable Insight
Insider selling volume is sub-material (0.016% of cap) and entirely compensation-driven. This cluster does not signal operational concern. Monitor next quarterly earnings for any guidance change or pipeline update that could drive the stock — the 30d prior insider flow was 2 sales at $2.1M, consistent with routine diversification. No trade-level action warranted.
Key Facts
- Cluster: 3 C-suite officers sold ~2.73M in open-market shares over 7 days (May 26 – June 2, 2026)
- Largest sale: CSO Onyia Jude sold $1.76M (11K shares at ~$160.25) after exercising options
- CRO Delaet Ingrid sold $354K; Chief Corp. Affairs Boyer D.W. sold $609K; CMO Keswani had only non-cash derivative activity
- Total open-market sales: ~$2.73M, or ~0.016% of $16.6B market cap — below the 0.1% materiality floor
- All sales were preceded by derivative exercises (M) or grants (A), consistent with compensation liquidity, not information-motivated selling
- No 10b5-1 plan designation was filed for any of these trades; non-10b5-1 sales carry slightly more signal than plan sales, but at 0.016% of cap the absolute magnitude is noise
Financial Impact
~$2.73M in insider open-market sales; immaterial relative to $16.6B market cap
Risk Factors
- Insider selling at low volume but by multiple C-suite members could indicate private caution even if below materiality floor
- Stock has significant pipeline concentration risk (Ingrezza, crinecerfont); any Phase 3/regulatory setback would hit all holders regardless of insider activity
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780610096737 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
Jun 2, 2026
3d ago
|
Insider Cluster
| $164.23 $166.83 | ▲ +1.58% | ▲ +1.18% | $163.88 (−0.21%) |
|
Jun 2, 2026
3d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
Jun 2, 2026
3d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 29, 2026
7d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 28, 2026
8d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 21, 2026
15d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 21, 2026
15d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 18, 2026
18d ago
|
Insider Cluster
| — | awaiting T+1 | — | — |
|
May 18, 2026
18d ago
|
8-K
| — | awaiting T+1 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access